Regeneron Pharmaceuticals announced that its Phase 3 melanoma trial for the drug combination Fianlimab + Libtayo failed to meet the primary endpoint against Merck's Keytruda. Despite earlier optimistic statements from company executives about potential positive outcomes, the trial results led to a sharp decline of over 10% in Regeneron's stock price. This failure has prompted an investigation into whether Regeneron made misleading statements about the trial's progress and expected results. Investors who suffered losses are being encouraged to seek legal advice regarding potential recovery options.
Pomerantz LLP is investigating a potential securities fraud lawsuit against Regeneron Pharmaceuticals following the company's announcement that its Phase 3 trial for a melanoma treatment failed to meet key endpoints. The trial results showed no signi...
Levi & Korsinsky has started an investigation into Regeneron Pharmaceuticals for potentially misleading investors about the results of a clinical trial. In March 2026, Regeneron's investor relations VP expressed hope for positive trial outcomes of a ...
